PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Melanoma

Study type: Observational

Funder types: Industry

Identifiers

NCT02492815

CA184-367

Details and patient eligibility

About

Observational study to evaluate the effectiveness and safety of ipilimumab, administered during the European expanded access programme (EAP) in pretreated patients with advanced (unresectable or metastatic) melanoma.

Full description

Minimum age: 18 years old (at time of inclusion in the CA184-367- but 16 for the EAP)

Enrollment: 1,773 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients have been enrolled in the EAPs
• Patients still alive must provide informed consent if required by local regulations
• Deceased patients are eligible per local regulations, their legal representatives must provide informed consent if required by local regulations

Exclusion criteria

• There are no specific exclusion criteria in this observational study other than the exclusion criteria of the EAP

Trial design

1,773 participants in 1 patient group

Population with condition and without condition

Description:

Participating in EAP